How is safety of dermatology drugs assessed: trials, registries, and spontaneous reporting

References

• Freeman EE. A seat at the big table: expanding the role of dermatology at the world health organization and beyond. J Invest Dermatol. 2014 Nov;134(11):2663–2665.
   PubMed Web of Science ®Google Scholar
• Lowell BA, Froelich CW, Federman DG, et al. Dermatology in primary care: prevalence and patient disposition. J Am Acad Dermatol. 2001;45(2):250–255.
   PubMed Web of Science ®Google Scholar
• Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American academy of dermatology association and the society for investigative dermatology. J Am Acad Dermatol. 2006;55:490–500.
   PubMed Web of Science ®Google Scholar
• Schofield JK, Grindlay D, William HC Skin conditions in the UK: a health needs assessment. 2009 [cited 2020 Jan 12]. www.nottingham.ac.uk/scs/divisions/evidencebaseddermatology/news/dermatologyhealthcareneedsassessmentreport.aspx
   Google Scholar
• Rapp, Rapp SR, Feldman SR, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999 Sep;41(3):401–407.
   PubMed Web of Science ®Google Scholar
• Mallon E, Newton JN, Klassen A, et al. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999 Apr;140(4):672–676.
   PubMed Web of Science ®Google Scholar
• Gooderham M, Papp K. The psychosocial impact of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 suppl 1):S19–22.
   PubMed Web of Science ®Google Scholar
• Li VW, Jaffe MP, Li WW, et al. Off-label dermatologic therapies: usage, risks, and mechanisms. Arch Dermatol. 1998;134(11):1449–1454.
   PubMed Web of Science ®Google Scholar
• Graves JE, Nunley K, Heffernan MP. Off label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol. 2007;56:e55–79.
   PubMedGoogle Scholar
• D’Erme AM, Romanelli M, Chiricozzi A. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy. Drug Des Devel Ther. 2017;11:1473–1480.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thac¸i D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–139.
   PubMed Web of Science ®Google Scholar
• Damsky W. King BA JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76:736–744.
   PubMed Web of Science ®Google Scholar
• Winder M, Viros A. Mechanisms of drug resistance in melanoma. Handb Exp Pharmacol. 2018;249:91–108.
   PubMedGoogle Scholar
• Chen A, Ali N, Boasberg P, et al. Clinical remission of cutaneous squamous cell carcinoma of the auricle with cetuximab and nivolumab. J Clin Med. 2018;7(1):10.
   PubMed Web of Science ®Google Scholar
• FDA statement on the voluntary withdrawal of raptiva from the U.S. market; (2009) [Cited 2020 Jan 5].
   Google Scholar
• Rawlins MD, Thompson JW. Pathogenesis of adverse drug ¬reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1977. p. 10.
   Google Scholar
• Barton S. Which clinical studies provide the best evidence? The best RCT still trumps the best observational study. BMJ. 2000;321:255–256.
   PubMed Web of Science ®Google Scholar
• Campa M, Ryan C, Menter A. Developing more open and equitable relationships with industry to improve advancements in clinical research in dermatology. Br J Dermatol. 2016;174:1365–1369.
   PubMed Web of Science ®Google Scholar
• Torre K, Shahriari M. Clinical trials in dermatology. Int J Women Dermatol. 2017;3(3):180–183.
   PubMedGoogle Scholar
• Garcia- Doval I, Carretero G, Vanaclocha F, et al. Risk of serious adverse events associated with biologic and non-biologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol. 2012;148(4):463–470.
   PubMedGoogle Scholar
• Mason KJ, Barker JNWN, Smith CH, et al., Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR. JAMA Dermatol. 2018;154(5): 581–588.
   PubMed Web of Science ®Google Scholar
• Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996;276:637–639.
   PubMed Web of Science ®Google Scholar
• Kim DY, Park HS, Cho S, et al. The quality of reporting randomized controlled trials in the dermatology literature in an era where the CONSORT statement is a standard. Br J Dermatol. 2019;180:1361–1367.
   PubMed Web of Science ®Google Scholar
• Lineberry N, Berlin JA, Mansi B, et al. Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. BMJ. 2016;355:i5078.
   PubMedGoogle Scholar
• Phillips R, Hazell L, Sauzet O, et al. Analysis and reporting of adverse events in randomised controlled trials: a review. BMJ Open. 2019;9:e024537.
   PubMedGoogle Scholar
• Frank C, Himmelstein DU, Woolhandler S, et al. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals. Health Aff. 2014;33:1453–1459.
   PubMed Web of Science ®Google Scholar
• Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology. 2019;58(10):p 1755–1766.
   PubMed Web of Science ®Google Scholar
• [Cited 2020 Jan 12th]. Available from: https://www.gov.uk/drug-safety-update/ingenol-mebutate-gel-picato-increased-incidence-of-skin-tumours-seen-in-some-clinical-studies
   Google Scholar
• Jansen MHE, Kessens JPHM, Nelemans PJ. et al. Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med. 2019 Mar;7(380):935.
   Google Scholar
• Magin P, Pond D, Smith W. Isotretinoin, depression and suicide: a review of the evidence. Br J Gen Pract. 2005;55(511):134–138.
   PubMed Web of Science ®Google Scholar
• Hui RL, Lide W, Chan J, et al. Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacother. 2009;43(12):1956–1963.
   PubMed Web of Science ®Google Scholar
• Patel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol. 2003;139(9):1184–1186.
   PubMedGoogle Scholar
• Castellsague J, Kuiper JG, Pottegård A, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (joint European longitudinal lymphoma and skin cancer evaluation - JOELLE study). Clin Epidemiol. 2018;10:299–310.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(1):81–89.
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–1189.
   PubMed Web of Science ®Google Scholar
• Foulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019;8:212570.
   PubMedGoogle Scholar
• Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence—what is it and what can it tell us? N Engl Med. 2016;375(23):2293–2297.
   PubMed Web of Science ®Google Scholar
• Reid CM. The role of clinical registries in monitoring drug safety and efficacy. Heart Lung Circ. 2015;24(11):1049–1052.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. The sentinel initiative: national strategy for monitoring medical product safety. May 2008 [Cited 2020 Jan 10]. Available from: http://www.fda.gov/oc/initiatives/advance/reports/report0508.pdf.
   Google Scholar
• Brooke EM. The current and future use of registers in health information systems. Geneva: World Health Organization; 1974. ( Publication No. 8).
   Google Scholar
• Blackburn SCF in pharmacoepidemiology and therapeutic risk management. Hartzema AG, Tilson HH, Chan KA, editors. Harvey Whitney Books. USA. 2008.
   Google Scholar
• Gliklich RE, Dreyer NA, eds. Registries for evaluating patient outcomes: a user’s guide. 2nd. (Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. d/b/a Outcome] under Contract No. HHSA29020050035I TO3.) AHRQ Publication No.10-EHC049. Rockville, MD: Agency for Healthcare Research and Quality; September2010.
   Google Scholar
• Burden AD, Warren RB, Kleyn CE, et al. The British association of dermatologists’ biologic interventions register (BADBIR): design, methodology and objectives. Br J Dermatol. 2012;166(3):545–554.
   PubMed Web of Science ®Google Scholar
• Warren R, Marsden A, Tomenson B, et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019;180:1069–1076.
   PubMed Web of Science ®Google Scholar
• Jabbar-Lopez ZK, Yiu ZZN, Ward V, et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol. 2017;137:1646–1654.
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biological therapies for the treatment of psoriasis: a prospective observational cohort study from the British association of dermatologists biologic interventions register (BADBIR). J Invest Dermatol. 2015;135:2632–2640.
   PubMed Web of Science ®Google Scholar
• Wilkinson N, Tsakok T, Dand N, et al. Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study. J Invest Dermatol. 2019;139(1):115–123.
   PubMed Web of Science ®Google Scholar
• Yiu ZZ, Exton LS, Jabbar-Lopez Z, et al. Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis. J Invest Dermatol. 2016;136:1584–1591.
   PubMed Web of Science ®Google Scholar
• Yiu Z, Smith CH, Ashcroft DM, et al. BADBIR study group (2018). Risk of serious infection in patients with psoriasis receiving biologic therapies: a prospective cohort study from the British association of dermatologists biologic interventions register (BADBIR). J Invest Dermatol. 2018;138(3):534–541.
   PubMed Web of Science ®Google Scholar
• Garcia-Doval I, Descalzo MA, Mason KJ, et al. Psonet network. cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of PSONET studies from Israel, Italy, Spain, the UK and Republic of Ireland. Br J Dermatol. 2018;179(4):863–871.
   PubMed Web of Science ®Google Scholar
• Trafford AM, Parisi R, Kontopantelis E, et al. Association of psoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(12):1390–1403.
   PubMed Web of Science ®Google Scholar
• Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133:144–153.
   PubMed Web of Science ®Google Scholar
• Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet. 1995;345(8949):567–569.
   PubMed Web of Science ®Google Scholar
• Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case series studies. Stat Methods Med Res. 2009;18(1):7–26.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Bonneh DY, Reuveni H, et al. Drug exposure and psoriasis vulgaris: case–control and case-crossover studies. Acta Derm Venereol. 2005;85(4):299–303.
   PubMed Web of Science ®Google Scholar
• Van Coevorden AM, Coenraads PJ, Svensson A, et al. Overview of studies of treatments for hand eczema-the EDEN hand eczema survey. Br J Dermatol. 2004;151:446–451.
   PubMed Web of Science ®Google Scholar
• WHO/EDM/QSM/2002.2; safety of medicines A guide to detecting and reporting adverse drug reactions. Why health professionals need to take action. Geneva: World Health Organization; 2002.
   Google Scholar
• Safety monitoring of medicinal products. guidelines for setting up and running a pharmacovigilance centre. Uppsala Monitoring Centre - WHO Collaborating Centre for International Drug Monitoring, EQUUS, London; 2000.
   Google Scholar
• [Cited 2020 Jan 5th]. Available from: https://www.gov.uk/guidance/the-yellow-card-scheme-guidance-for-healthcare-professionals
   Google Scholar
• Vallano A, Cereza G, Pedros C, et al. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol. 2005;60:653–658.
   PubMed Web of Science ®Google Scholar
• White T, Arakelian A, Rho JP. Counting the cost of drug-related adverse events. Pharmacoeconomics. 1999;15:445–458.
   PubMed Web of Science ®Google Scholar
• Hazell L, Shakir SA. Under-reporting of adverse drug reactions: A systematic review. Drug Saf. 2006;29:385–396.
   PubMed Web of Science ®Google Scholar
• Inman WH. Attitudes to adverse drug reactions reporting. Br J Clin Pharmacol. 1996;41:434–435.
   PubMed Web of Science ®Google Scholar
• Herdeiro MT, Figueiras A, Polonia J, et al. Physicians’ attitudes and adverse drug reaction reporting: A case- control study in Portugal. Drug Saf. 2005;28:825–833.
   PubMed Web of Science ®Google Scholar
• The angiogenesis foundation industry database; 1998.
   Google Scholar
• DiMarco G, Hill D, Feldman SR. Review of patient registries in dermatology. J Am Acad Dermatol. 2016;75(4):824–829.
   PubMed Web of Science ®Google Scholar
• Elbendary A, Kellen R. Off-label uses of biologic agents approved for psoriasis and psoriatic arthritis for dermatological conditions: part II. J Psoriasis Psoriatic Arthritis. 2017;2(2):65–72.
   Google Scholar
• Li VW, Jaffe MP, Li WW, et al. Off-label dermatologic therapies: usage, risks, and mechanisms. Arch Dermatol. 1998;134(11):1449–1454.
   PubMed Web of Science ®Google Scholar
• [Cited 2020 Jan 10th]. Available from: https://www.gov.uk/drug-safety-update/off-label-or-unlicensed-use-of-medicines-prescribers-responsibilities
   Google Scholar
• Rodwin MA. Rooting out institutional corruption to manage inappropriate off-label drug use. J Law, Med & Ethics. 2013;41(3):654–664.
   PubMed Web of Science ®Google Scholar
• Capella GL, Grigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur J Dermatol. 2001;11(3):209–213.
   PubMed Web of Science ®Google Scholar
• McBayne TO, Siddall OM. Montelukast treatment of urticaria. Ann Pharmacother. 2006;40(5):939–942.
   PubMed Web of Science ®Google Scholar
• Benard B, Bastien V, Vinet B, et al. Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice. Eur Respir J. 2017;50:1700148.
   PubMed Web of Science ®Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827–836.
   PubMed Web of Science ®Google Scholar
• Lowe KE, Mansfield KE, Delmestri A, et al. Atopic eczema and fracture risk in adults: A population-based cohort study. J Allergy Clin Immunol. 2020;145(2):563–571.
   Web of Science ®Google Scholar
• Aalto-Korte K, Turpeinen M. Quantifying systemic absorption of topical hydrocortisone in erythroderma. Br J Dermatol. 1995;133:403–408.
   PubMed Web of Science ®Google Scholar
• Hon KLE, Leung TF, Kam WYC, et al. Dietary restriction and supplementation in children with atopic eczema. Clin Exp Dermatol. 2006;31:187–191.
   PubMed Web of Science ®Google Scholar
• Ikram MA, Brusselle GGO, Murad SD, et al. The rotterdam study: 2018 update on objectives, design and main results. Eur J Epidemiol. 2017;32:807–850.
   PubMed Web of Science ®Google Scholar
• Maret-Ouda J, Tao W, Wahlin K, et al. Nordic registry-based cohort studies: possibilities and pitfalls when combining Nordic registry data. Scand J Public Health. 2017;45(17_suppl):14–19.
   PubMed Web of Science ®Google Scholar
• Sankila R, Garwicz S, Olsen JH, et al. Risk of subsequent malignant neoplasms among 1,641 hodgkin’s disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. J clin oncol. 1996;14(5):1442–1446.
   PubMed Web of Science ®Google Scholar
• Behrman RE, Benner JS, Brown JS, et al. Developing the sentinel system- a national resource for evidence development. N Engl J Med. 2011;364:498–499.
   PubMed Web of Science ®Google Scholar
• The sentinel initiative: national strategy for monitoring medical product safety. Silver Spring, MD: Food and Drug Administration, May 2008 [cited 2020 Jan 12]. (http://www.fda.gov/downloads/Safety/FDAsSentinelInitiative/UCM124701.pdf.)
   Google Scholar
• Platt R, Brown JS, Robb M, et al. The FDA sentinel initiative- an evolving national resource. N Engl J Med. 2018;379:2091–2093.
   PubMed Web of Science ®Google Scholar
• Pinn VW. Sex and gender factors in medical studies. JAMA. 2003;289:397–400.
   PubMed Web of Science ®Google Scholar
• Kemmett D, Tidman MJ. The influence of the menstrual cycle and pregnancy on atopic dermatitis. Br J Dermatol. 1991;125:59–61.
   PubMed Web of Science ®Google Scholar
• Murase JE, Chan KK, Garite TJ, et al. Hormonal effect on psoriasis in pregnancy and postpartum. Arch Dermatol. 2005;141(1):601–606.
   PubMedGoogle Scholar
• Youssef P, Kennedy D. Arthritis in pregnancy: the role and safety of biological agents. Obstet Med. 2009 Dec;2(4):134–137.
   PubMedGoogle Scholar
• Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol. 2008;59(2):295–315.
   PubMed Web of Science ®Google Scholar
• [Cited 2020 Jan 10th]. Available from: https://www.fda.gov/science-research/womens-health-research/list-pregnancy-exposure-registries
   Google Scholar
• Chambers C, Johnson DL, Kiernan E. Approach to evaluating pregnancy safety of anti-rheumatic medications in the OTIS mothertoBaby pregnancy studies: what have we learned? Rheumatology (Oxford). 2018 Jul;57(Suppl 5):v34–v39.
   PubMedGoogle Scholar
• Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the food and drug administration database. J Rheumatol. 2009;36:635–641.
   PubMed Web of Science ®Google Scholar
• Crijns HJ, Jentink J, Garne E, et al. The distribution of congenital anomalies within the VACTERL association among tumor necrosis factor antagonist-exposed pregnancies is similar to the general population. J Rheumatol. 2011;38:1871–1874.
   PubMed Web of Science ®Google Scholar
• Yiu ZZN, Griffiths CEM, Warren RB. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. Br J Derm. 2014;171(3):485–491.
   PubMed Web of Science ®Google Scholar
• Lebwohl, Blauvelt A, Paul C. et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018;266–276.
   PubMed Web of Science ®Google Scholar
• European union: strategic research agenda for innovative medicines initiative. [Cited 2020 Jan 10]. Available from: http://www.efpia.eu/uploads/modules/documents/def-efpia-brochure-sra-a4-web.pdf
   Google Scholar
• Zhang G, Nebert DW. Personalized medicine: genetic risk prediction of drug response. Pharmacol Ther. 2017 Jul;175:75–90.
   PubMed Web of Science ®Google Scholar
• Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, et al. Relationship between the HLA-B*1502 allele and carbamazepine-induced stevens-johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(9):1025–1032.
   PubMed Web of Science ®Google Scholar
• Ferrell PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens- Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008 Oct;9(10):1543–1546.
   PubMed Web of Science ®Google Scholar
• Noe MH, Gelfand JM. Research techniques made simple: pharmacoepidemiology research methods in dermatology. J Invest Dermatol. 2018 Feb;138(2):e13–e18.
   PubMed Web of Science ®Google Scholar